PROJECT TEAM
Katrine Prier Lindvig, MD. PhD fellow, Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital
THE NEED
Fatty Liver Disease is one of the fastest-growing health challenges, responsible for over 1 million deaths annually worldwide. In Denmark, 75% of high-risk patients remain undiagnosed until late-stage cirrhosis, where 85% die within five years. Current diagnostic tools like ALAT are outdated and only 53% accurate, leading to both missed diagnoses and redundant specialist referrals.
THE SOLUTION
LiverPRO uses AI to analyze nine widely available blood markers, providing a risk score for advanced liver fibrosis with 92% accuracy. Integrated into existing workflows, it leverages routine blood samples to deliver precision diagnostics without additional testing. This approach allows general practitioners to detect high-risk patients early, while minimizing unnecessary referrals and follow-up procedures.
LiverPro/EVIDO - Odense Univerity Hospital
Call 1 - 2022
500.000 DKK
Clinical Area
Hepatology, Metabolic Disease
Technology
AI
PROJECT SUMMARY
LiverPRO is an AI-powered clinical decision support tool that detects advanced Fatty Liver Disease (FLD) with high accuracy using existing blood tests. Designed for primary care, it enables early identification of high-risk patients, reduces unnecessary referrals, and optimizes patient pathways—ultimately improving survival and reducing healthcare costs.
CLINICAL IMPACT
LiverPRO supports early treatment to prevent disease progression, significantly prolonging patient and organ health. It improves care quality by enabling accurate, non-invasive screening in primary care, reducing complications from late diagnoses, and lowering healthcare costs by over 20% through better resource allocation and fewer redundant specialist evaluations.